Molecular design toward dual-modality probes for radioisotope-based imaging (PET or SPECT) and MRI

US9463254B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9463254-B2
Application numberUS-201414298688-A
CountryUS
Kind codeB2
Filing dateJun 6, 2014
Priority dateJun 7, 2013
Publication dateOct 11, 2016
Grant dateOct 11, 2016

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

In some aspects, the present invention provides novel ligands, which may be used to make novel dual-modality imaging agents, for example, for PET and MRI imaging. In further aspects, by the present disclosure also provides methods of use and methods of preparation of the novel ligands, metal complexes, and imaging agents thereof.

First claim

Opening claim text (preview).

What is claimed: 1. A compound of the formula: wherein: R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are each independently selected from X 1 , X 2 , and X 3 are each independently alkanediyl (C≦12) , alkenediyl (C≦12) , alkynediyl (C≦12) , arenediyl (C≦12) , heteroarenediyl (C≦12) , alkoxydiyl (C≦12) , alkylaminodiyl (C≦12) , or a substituted version of any of these groups; or an amino acid residue, an amino acid residue linked to a targeting moiety, a PEG linker comprising between 2 and 200 repeating units; Y 1 , Y 2 , Y 3 , Y 4 , Y 5 , and Y 6 are each independently alkanediyl (C≦12) , alkenediyl (C≦12) , alkynediyl (C≦12) , arenediyl (C≦12) , heteroarenediyl (C≦12) , alkoxydiyl (C≦12) , alkylaminodiyl (C≦12) , or a substituted version of any of these groups; or an amino acid residue, an amino acid residue linked to a targeting moiety, a PEG linker comprising between 2 and 200 repeating units; and provided that all of R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 are not or a metal complex or salt thereof. 2. The compound of claim 1 , wherein the compound is further defined as: or a metal complex or salt thereof.

Assignees

Inventors

Classifications

  • General or multifunctional contrast agents, e.g. chelated agents · CPC title

  • conjugates with carriers being macromolecules · CPC title

  • A61K49/14Primary

    Peptides, e.g. proteins · CPC title

  • dendrimers, dendrons, hyperbranched compounds · CPC title

  • conjugates with carriers being peptides, polyamino acids or proteins (antibodies A61K51/10) · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9463254B2 cover?
In some aspects, the present invention provides novel ligands, which may be used to make novel dual-modality imaging agents, for example, for PET and MRI imaging. In further aspects, by the present disclosure also provides methods of use and methods of preparation of the novel ligands, metal complexes, and imaging agents thereof.
Who is the assignee on this patent?
Univ Texas, Univ Texas
What technology area does this patent fall under?
Primary CPC classification A61K49/14. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Oct 11 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).